Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorWicklein, Rebecca
dc.contributor.authorYam, Charmaine
dc.contributor.authorNoll, Christina
dc.contributor.authorAly, Lilian
dc.contributor.authorBanze, Nicolas
dc.contributor.authorRomahn, Eva Feodora
dc.contributor.authorCabello, Sergio
dc.contributor.authorVidal-Jordana, Angela
dc.date.accessioned2023-10-18T07:49:26Z
dc.date.available2023-10-18T07:49:26Z
dc.date.issued2023-11
dc.identifier.citationWicklein R, Yam C, Noll C, Aly L, Banze N, Romahn EF, et al. The OSCAR-MP Consensus Criteria for Quality Assessment of Retinal Optical Coherence Tomography Angiography. Neurol Neuroimmunol Neuroinflamm. 2023 Nov;10(6):e200169.
dc.identifier.issn2332-7812
dc.identifier.urihttps://hdl.handle.net/11351/10467
dc.descriptionConsensus; Angiography; Retina
dc.description.abstractBackground and Objectives Optical coherence tomography angiography (OCTA) is a noninvasive high-resolution imaging technique for assessing the retinal vasculature and is increasingly used in various ophthalmologic, neuro-ophthalmologic, and neurologic diseases. To date, there are no validated consensus criteria for quality control (QC) of OCTA. Our study aimed to develop criteria for OCTA quality assessment. Methods To establish criteria through (1) extensive literature review on OCTA artifacts and image quality to generate standardized and easy-to-apply OCTA QC criteria, (2) application of OCTA QC criteria to evaluate interrater agreement, (3) identification of reasons for interrater disagreement, revision of OCTA QC criteria, development of OCTA QC scoring guide and training set, and (4) validation of QC criteria in an international, interdisciplinary multicenter study. Results We identified 7 major aspects that affect OCTA quality: (O) obvious problems, (S) signal strength, (C) centration, (A) algorithm failure, (R) retinal pathology, (M) motion artifacts, and (P) projection artifacts. Seven independent raters applied the OSCAR-MP criteria to a set of 40 OCTA scans from people with MS, Sjogren syndrome, and uveitis and healthy individuals. The interrater kappa was substantial (κ 0.67). Projection artifacts were the main reason for interrater disagreement. Because artifacts can affect only parts of OCTA images, we agreed that prior definition of a specific region of interest (ROI) is crucial for subsequent OCTA quality assessment. To enhance artifact recognition and interrater agreement on reduced image quality, we designed a scoring guide and OCTA training set. Using these educational tools, 23 raters from 14 different centers reached an almost perfect agreement (κ 0.92) for the rejection of poor-quality OCTA images using the OSCAR-MP criteria. Discussion We propose a 3-step approach for standardized quality control: (1) To define a specific ROI, (2) to assess the occurrence of OCTA artifacts according to the OSCAR-MP criteria, and (3) to evaluate OCTA quality based on the occurrence of different artifacts within the ROI. OSCAR-MP OCTA QC criteria achieved high interrater agreement in an international multicenter study and is a promising QC protocol for application in the context of future clinical trials and studies.
dc.language.isoeng
dc.publisherWolters Kluwer Health
dc.relation.ispartofseriesNeurology, Neuroimmunology and Neuroinflammation;10(6)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectRetina - Imatgeria
dc.subjectAngiografia
dc.subjectTomografia
dc.subject.meshTomography, Optical Coherence
dc.subject.meshAngiography
dc.subject.meshRetina
dc.subject.mesh/diagnostic imaging
dc.titleThe OSCAR-MP Consensus Criteria for Quality Assessment of Retinal Optical Coherence Tomography Angiography
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1212/NXI.0000000000200169
dc.subject.decstomografía de coherencia óptica
dc.subject.decsangiografía
dc.subject.decsretina
dc.subject.decs/diagnóstico por imagen
dc.relation.publishversionhttps://doi.org/10.1212/NXI.0000000000200169
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Wicklein R] Department of Neurology, Klinikum rechts der Isar, TUM School of Medicine, Technical University of Munich, Germany. [Yam C] Department of Neuroinflammation, Queen Square MS Centre, Faculty of Brain Sciences, UCL Queen Square Institute of Neurology, University College London. Neurosciences Institute, Cleveland Clinic London, United Kingdom. [Noll C, Aly L, Banze N, Romahn EF] Department of Neurology, Klinikum rechts der Isar, TUM School of Medicine, Technical University of Munich, Germany. [Cabello S, Vidal-Jordana A] Servei de Neurologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain
dc.identifier.pmid37813596
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/PE2017-2020/PI17%2F02162
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/PEICTI2021-2023/PI22%2F01589
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record